STAT July 20, 2022
Nicholas Florko

WASHINGTON — Democrats may be closer than ever to passing sweeping drug pricing reforms, but Sen. Ron Wyden says there’s more to do.

During a STAT event Wednesday, the Oregon Democrat, who chairs the powerful Senate Finance Committee, outlined a number of additional policies he wants to turn to after the Senate passes the reforms currently up for consideration. That package would deliver on Democrats’ promise to allow Medicare to negotiate over the price of drugs, and would penalize drug makers for hiking their prices faster than inflation.

“It certainly … is a strong start,” Wyden said. “There’s plenty more to do.”

That “plenty more” was in specific reference to one of Wyden’s biggest wish-list items: major changes to the...

Today's Sponsors

Amwell
Oliver Wyman
Upfront Healthcare

Today's Sponsors

Qure4u
H1

Today's Sponsor

HealthITq

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending
How Should Medicare Negotiate Drug Prices? A Summary of the Options
4sight Friday | Only One Sure Winner in Medicare Drug Negotiations | 10 Things Doctors Say | Provider Health IT Priorities
Medicare Drug Price Negotiation: Real Savings or Just Another Shell Game?
HHS Implements Inflationary Rebates For List Prices Of Medicare Part D (Outpatient) Drugs
CMS: Medicare Advantage, drug plan premiums decline for 2023